Exenatide is an incretin mimic that acts as an agonist at the glucagon-like peptide 1 receptor to enhance insulin secretion in the presence of raised glucose concentrations.  It is a 39-amino-acid peptide an insulin secretagogue with glucoregulatory effects. It displays biological properties similar to human glucagon-like peptide-1 (GLP-1), a regulator of glucose metabolism and insulin secretion. In contrast to DA-3091, which exhibited an HbA1c-lowering effect even at 0.1 mg/kg dose, the median effective exenatide dose [ED50] for Byetta® LAR was reported to be 74 μg, which approximately corresponded to an exenatide dose of 0.2 mg/kg.